Barbara Santevecchi

Barbara Santevecchi, PharmD, BCIDP

Clinical Assistant Professor

Department: Pharmacy Education and Practice
Business Phone: (352) 594-5892
Business Email: bsantevecchi@ufl.edu

About Barbara Santevecchi

Barbara Santevecchi joined the College of Pharmacy as a Clinical Assistant Professor in the Department of Pharmacy Education and Practice in August 2019. She serves as an Infectious Diseases Clinical Pharmacy Specialist and member of the Antimicrobial Management Program at UF Health Shands Hospital. She received her Doctor of Pharmacy degree from Wingate University School of Pharmacy in Wingate, North Carolina in 2015. Following graduation, she completed PGY1 Pharmacy Practice and PGY2 Infectious Diseases pharmacy residencies at the Medical University of South Carolina in Charleston, South Carolina. After completing residency training, she worked as an Infectious Diseases Clinical Pharmacist at Atrium Health in Charlotte, North Carolina. Barbara is a board certified infectious diseases pharmacist. Her research interests include HIV/AIDS, microbiology, rapid diagnostics, novel agents for multidrug resistant infections, and antimicrobial stewardship. Barbara has published research in several peer-reviewed journals and has delivered presentations on her research at national meetings. She is an active member of the Society of Infectious Diseases Pharmacists, Infectious Diseases Society of America, and American Association of Colleges of Pharmacy.

Accomplishments

Board Certification (BCIDP) Committee Vice Chair
2023-2024 · Society of Infectious Diseases Pharmacists
Exemplary Clinician Award
2022-2023 · University of Florida College of Pharmacy
Teaching Service Award
2021 · University of Florida College of Pharmacy
Media Excellence Award
2020 · University of Florida College of Pharmacy
Preceptor of the Year
2019-2020 · UF Health Shands Hospital Pharmacy Residency Program
Member
2016-Current · Infectious Diseases Society of America
Member
2013-Current · American College of Clinical Pharmacy

Teaching Profile

Courses Taught
2019-2023
PHA5788C Patient Care 6
2020-2023
PHA5782C Patient Care 2: Introduction to Infectious Disease and Oncology
2020
PHA5755 Micro, Immun, Virol
2019
PHA5163L Prac Skills Lab III
2021-2024
PHA5784C Pt Care 4: GI and Renal
2021-2024
PHA5876C Pt Care 8 Complex Pts

Board Certifications

  • Board Certified Infectious Diseases Pharmacist
    Board of Pharmacy Specialties

Research Profile

Research Interests: Microbiology, rapid diagnostics, HIV/AIDS, novel agents for multidrug resistant infections, antimicrobial stewardship

Open Researcher and Contributor ID (ORCID)

0000-0001-5239-8303

Publications

2024
Brincidofovir for disease progression due to suspected tecovirimat resistance in association with advanced HIV.
International journal of STD & AIDS. [DOI] 10.1177/09564624241238813. [PMID] 38502040.
2023
Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI).
JAC-antimicrobial resistance. 5(2) [DOI] 10.1093/jacamr/dlad021. [PMID] 36936190.
2022
Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics
Antimicrobial Agents and Chemotherapy. 66(2) [DOI] 10.1128/aac.02046-21. [PMID] 34902271.
2022
Impact of Empiric Linezolid for Necrotizing Soft Tissue Infections on Duration of Methicillin-Resistant Staphylococcus aureus-Active Therapy.
Surgical infections. 23(3):313-317 [DOI] 10.1089/sur.2021.329. [PMID] 35133888.
2022
Implementation of a β-lactam therapeutic drug monitoring program: Experience from a large academic medical center.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 79(18):1586-1591 [DOI] 10.1093/ajhp/zxac171. [PMID] 35704702.
2022
Pharmacy student self-assessment of strength of residency candidacy compared to clinical faculty.
Currents in pharmacy teaching & learning. 14(3):304-309 [DOI] 10.1016/j.cptl.2022.01.017. [PMID] 35307089.
2022
Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)
Antimicrobial Stewardship & Healthcare Epidemiology. 2(1) [DOI] 10.1017/ash.2022.21. [PMID] 36310806.
2021
Impact of supplemental individual verbal defense on confidence, engagement, and performance in a team-based learning therapeutics course.
Currents in pharmacy teaching & learning. 13(2):152-158 [DOI] 10.1016/j.cptl.2020.09.010. [PMID] 33454072.
2021
Implementation of a comprehensive intervention focused on hospitalized patients with HIV by an existing stewardship program: successes and lessons learned.
Therapeutic advances in infectious disease. 8 [DOI] 10.1177/20499361211010590. [PMID] 33953916.
2020
Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection
Annals of Pharmacotherapy. 54(12):1252-1259 [DOI] 10.1177/1060028020933772.
2018
Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
International journal of antimicrobial agents. 51(4):629-635 [DOI] 10.1016/j.ijantimicag.2018.01.016. [PMID] 29408227.
2018
In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates.
Open forum infectious diseases. 5(7) [DOI] 10.1093/ofid/ofy158. [PMID] 30046642.
2015
Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
The Annals of pharmacotherapy. 49(5):566-81 [DOI] 10.1177/1060028015570729. [PMID] 25680759.

Grants

Jun 2021 ACTIVE
A retrospective chart review study of cefiderocol real world outcomes and safety in the treatment of patients with Gram-negative bacterial infections (GNBI) in the US and Europe
Role: Principal Investigator
Funding: SHIONOGI INC
May 2021 ACTIVE
Prevalence of Cefazolin Inoculum Effect in Mcthicillin Susceptible Staphylococcus aureus Bacteremia
Role: Co-Project Director/Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL

Education

Pharm.D.
2015 · Wingate University School of Pharmacy

Contact Details

Phones:
Business:
(352) 594-5892
Emails:
Addresses:
Business Mailing:
PO Box 100486
GAINESVILLE FL 32610
Business Street:
PO Box 100486
GAINESVILLE FL 32610